Get Adobe Flash player

Policing your Donuts: FDA Tentatively Determines that Trans Fats from Partially Hydrogenated Oils (PHOs) are not Generally Recognized as Safe (GRAS)

By John Moore, Venable LLP

Today the U.S. Food and Drug Administration (FDA) issued a notice, due to publish in tomorrow’s Federal Register, tentatively determining that partially hydrogenated oils (PHOs) are not generally recognized as safe (GRAS) for use in food.  If this determination is finalized, PHOs would effectively be banned from use in foods unless they are first approved by FDA as “food additives,” which would likely be difficult.  This would have a major impact on the food industry.  In particular, products such as donuts, cookies, margarine, microwave popcorn, frozen pizzas, baked goods, frostings, and many other foods would need to be reformulated.

FDA’s concern focuses on trans fats, which are deliberately produced in the manufacturing process for PHOs to help increase the melting point, shelf life, and flavor stability of the oil.  Although trans fats exist elsewhere in the diet to some extent, PHOs are the major source.  According to FDA, trans fats may have adverse effects on blood cholesterol parameters that affect the risk of coronary heart disease (CHD), and may have other health implications that, as FDA acknowledges, are unconfirmed.  This tentative determination that PHOs are not GRAS follows a 2003 rule requiring labeling of trans fat content in nutrition labeling, as well as various state and local initiatives that have restricted the use of PHOs.

FDA has established a 60-day public comment period from publication of the notice.  Given the complexity and economic significance of the tentative finding, it is likely that this period could be extended if requested by stakeholders noting a need for more time to prepare fulsome comments.  Besides requesting comments on whether FDA should finalize its tentative determination, the Agency also requests comments on:

  • Other possible approaches to addressing PHOs in food, such as setting trans fat specification levels.
  • How long reformulation would take.
  • What would be a reasonable compliance date to allow adequate time for reformulation while minimizing market disruption?  (The notice hints that a “multi-year compliance period” may be allowed.)
  • How can the burden on small businesses be reduced?
  • What other challenges may exist, such as products that cannot be reformulated?
  • Whether there is a “prior sanction” for the use of PHO in food of which FDA is unaware.

The pre-publication version of the notice is available at


John Moore is an Of Counsel in Venable LLP’s  Washington office. Dr. Moore, who holds a PhD in chemistry, previously worked for food manufacturers overseeing production. Dr. Moore’s practice focuses on the full spectrum of federal and state food and drug regulations, covering packaged foods, food additives, food contact substances, dietary supplements, alcoholic beverages, biologics, as well as consumable products of biotechnology.

Find it HERE first!
Follow me on Twitter